跳转至内容
Merck
CN
  • Arylacetamide Deacetylase Is Involved in Vicagrel Bioactivation in Humans.

Arylacetamide Deacetylase Is Involved in Vicagrel Bioactivation in Humans.

Frontiers in pharmacology (2017-12-07)
Jinfang Jiang, Xiaoyan Chen, Dafang Zhong
摘要

Vicagrel, a structural analog of clopidogrel, is now being developed as a thienopyridine antiplatelet agent in a phase II clinical trial in China. Some studies have shown that vicagrel undergoes complete first-pass metabolism in human intestine, generating the hydrolytic metabolite 2-oxo-clopidogrel via carboxylesterase-2 (CES2) and subsequently the active metabolite H4 via CYP450s. This study aimed to identify hydrolases other than CES2 that are involved in the bioactivation of vicagrel in human intestine. This study is the first to determine that human arylacetamide deacetylase (AADAC) is involved in 2-oxo-clopidogrel production from vicagrel in human intestine.

材料
货号
品牌
产品描述

Sigma-Aldrich
2-溴-3′-甲氧基苯乙酮, 98%
登录查看公司和协议定价
货号包装规格是否有货价格数量
5 mg
请联系客服了解存货情况
新价格,新优惠!
CN¥1,550.72
10 mg
预计发货时间 March 03, 2025
详情...
新价格,新优惠!
CN¥2,890.04
25 mg
请联系客服了解存货情况
新价格,新优惠!
CN¥5,310.80
100 mg
请联系客服了解存货情况
新价格,新优惠!
CN¥17,128.82